ANX005 Phase 2 Full Data Results Community Letter:

Dear Huntington’s disease community:

Today, Annexon Biosciences announced positive results from a Phase 2 clinical trial evaluating ANX005 in people with Huntington’s disease (HD). ANX005 is an investigational monoclonal antibody designed to inhibit part of the immune system – specifically the complement pathway. Evidence suggests that the complement pathway plays a key role in inappropriately damaging and removing functioning synapses, or nerve connections in the brain, that leads to neurodegeneration in disorders such as HD. The results of this trial are promising, and support the continued development of ANX005 to treat HD.

The Phase 2 study was conducted in multiple US treatment centers, and evaluated 28 adults diagnosed with, or at risk for, early manifest HD. Participants were evaluated over 9 months—six months of treatment with ANX005 and three months off treatment. The trial was designed to assess primarily the safety and tolerability of ANX005, as well as various clinical measures.

The results of the trial show that ANX005 was generally well tolerated, with first dose infusion-related reactions primarily in the form of a transient skin rash being the most frequent adverse events. Importantly, ANX005 fully blocked the classical complement pathway in both the blood and brain as measured by CSF for the entire six-month treatment period and well into the three-month follow-up period. In addition, over half of the participants treated with ANX005 showed encouraging stabilization of their disease, and in some instants even improvement, on clinical outcome measures such as progression of motor, cognitive and functional capacity.

We would like to express our sincere gratitude to the trial participants and their families, the clinical investigators, and all those in the HD community who made this clinical trial possible. We will discuss the trial results with regulators while also planning the next stage of study of ANX005 as a treatment for HD. We look forward to providing additional updates on next steps for the program as they become available.

For additional information, please contact Kris Fortner at kfortner@annexonbio.com. You can view the full press release and overview presentation here: https://ir.annexonbio.com/events-and-presentations/events.

Sincerely,
The Annexon team